Bibliographical note

Funding Information:
E.L.S. reports grants and fees for participation as a consultant and principal investigator from Eli Lilly and Company, LEO Pharma, Pfizer and Regeneron; grants for participation as a principal investigator from Galderma and Merck & Co.; and fees for consultant services from AbbVie, Boehringer Ingelheim, Dermavant Sciences, Incyte, FortéBio, Pierre Fabre and Sanofi‐Genzyme. R.B. is an investigator, consultant, advisory board member, speaker for and/or receives honoraria from AbbVie, Antiobix, Aquinox Pharmaceuticals, Asana, Astellas, Boehringer Ingelheim, Brickell Biotech, Dermavant Sciences, Dermira, Dignity Sciences, Eli Lilly and Company, Galderma, GlaxoSmithKline‐Stiefel, Glenmark, Hoffman‐LaRoche Ltd, Incyte, Kiniksa, LEO Pharma, Neokera, Pfizer, Regeneron, Relaxer, Sanofi, Sienna and Vitae; and is an employee and shareholder of Innovaderm Research. A.S.P. has been an investigator for AbbVie, AnaptysBio, Eli Lilly and Company, Incyte, LEO Pharma and Regeneron, a consultant with honorarium from AbbVie, Almirall, AnaptysBio, Asana Bio, Boehringer Ingelheim, Dermavant Sciences, Dermira, Eli Lilly and Company, Forté, Incyte, LEO Pharma, Novartis, Regeneron and Sanofi, and on a data safety monitoring board with fees from Galderma. B.K. has served on advisory boards and/or is a consultant and/or is a clinical trial investigator for AbbVie, Aclaris Therapeutics, AltruBio, Almirall, AnaptysBio, Arena Pharmaceuticals, Bioniz Therapeutics, Bristol Meyers Squibb, Concert Pharmaceuticals, Dermavant Sciences, Horizon Therapeutics, Eli Lilly and Company, Incyte Corp, LEO Pharma, Otsuka/Visterra, Pfizer, Regeneron, Sanofi‐Genzyme, TWi Biotechnology and Viela Bio. He is on speaker bureaus for Pfizer, Regeneron and Sanofi‐Genzyme. J.I.S. reports honoraria for consultant and advisory board services and for participation as an investigator from Eli Lilly and Company. K.R. has served as advisor and/or paid speaker for and/or participated in clinical trials sponsored by AbbVie, Affibody, Almirall, Amgen, Avillion, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Centocor, Covagen AG, Eli Lilly and Company, Forward Pharma, Fresenius Medical Care, Galapagos, GlaxoSmithKline, Janssen‐Cilag, Kyowa Kirin, LEO Pharma, Medac, Merck Sharp & Dohme, Miltenyi Biotec, Novartis, Ocean Pharma, Pfizer, Regeneron, Samsung Bioepis, Sanofi, Sun Pharma, Takeda, UCB, Valeant and Xenoport. J.P.T. is an advisor for AbbVie, Almirall, Arena Pharmaceuticals, Aslan Pharmaceuticals, Coloplast, Eli Lilly & Co, LEO Pharma, OM Pharma, Pfizer, Regeneron, Sanofi‐Genzyme and Union Therapeutics; a speaker for AbbVie, Almirall, Eli Lilly & Co, LEO Pharma, Pfizer, Regeneron and Sanofi‐Genzyme; and received research grants from Pfizer, Regeneron and Sanofi‐Genzyme. H.D. was an employee of Clinical Outcome Solutions, contracted by Eli Lilly and Company. L.S., A.M.DeL. and F.P.N. are employees of and stockholders in Eli Lilly and Company. L.F.E. reports grants and fees for participation as a consultant and/or investigator from AbbVie, Almirall, Aslan, Dermavant, Dermira, Eli Lilly and Company, Forté Biosciences, Galderma, Incyte, LEO Pharma, Novartis, Pfizer, Regeneron and Sanofi‐Genzyme; and honoraria and fees from Asana and Glenmark for data safety monitoring board services.

Funding Information:
Medical writing support was provided by Thomas Melby, and editorial support was provided by Antonia Baldo, both of Syneos Health, funded by Eli Lilly and Company.